IRVINE, Calif., March 7, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced financial results for the three and twelve-month periods ended...
Tailwinds' Take: a very positive development as, despite great fundamentals, the Street knew that CYRX would need to raise money at some point. I expect the stock to trade much better now with financing behind them and...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
There's a veritable gold rush going on right now in the area of personalized therapies. Companies like Novartis and Gilead (KITE) were among the first to hit the pay zone, but there's plenty of gold in them thar hills,...
Tailwinds' Take: this stock represents the definition of "tailwinds". They have a very large secular move happening underneath them and they are the only option when it comes to shipping these therapeutics, so are a direct beneficiary of all...
IRVINE, Calif., March 6, 2018 /PRNewswire/ -- Cryoport, Inc. (CYRX) (CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced financial results for the three and twelve-month periods ended December 31, 2017. Jerrell Shelton,...
Tailwinds' Take: Very big news for Cryoport. McKesson is late to the regenerative therapy game and are trying to aggressively play catch-up with Cardinal Health (partners with Novartis and Gilead, but also using Cryoport in this capacity). As the...
IRVINE, California, February 5, 2018 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Company”), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced that Cryoport will support TiGenix (Euronext Brussels and NASDAQ: TIG) as it...
As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear lately, closing the year with a bang. If gaining 20% in the last two months...
Yesterday an article came out on Bloomberg that discussed the issues with reimbursement on Gilead's latest drug, Yescarta. For those who don't know, Yescarta is a CAR-T therapy that was developed by KITE Pharmaceuticals. CAR-T is the hottest space...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.